ADVI Aware: Key Health Policy Topics in June 2023
ADVI Aware is a monthly snapshot look back of key health policy topics and a brief look ahead for upcoming meetings and expected activities.
ADVI’s June Issue Includes:
IRA Update: CMS Issues Revised Negotiation Guidance (link)
CMS Releases CY 2024 ESRD PPS Proposed Rule (link)
CMS Issues Transitional Coverage for Emerging Technologies Notice (link)
Upcoming Meeting and Expected Activities
- September 7-8: MedPAC (link)
- September 18-19: PTAC (link)
- September 21-22: MACPAC Public Meeting (link)
- October 5-6: MedPAC (link)
- November 2-3: MedPAC (link)
- November 2-3: MACPAC Public Meeting (link)
- December 4-5: PTAC (link)
- December 7-8 MedPAC (link)
- December 14-15: MACPAC Public Meeting (link)
- January 25-26, 2024: MACPAC Public Meeting (link)
- March 7-8, 2024: MACPAC Public Meeting (link)
- April 11-12, 2024: MACPAC Public Meeting (link)
This is a delayed release. ADVI Aware is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.
CEO insights
Related articles
Real analysis from people who’ve been there
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption
Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …
Marc Samuels, JD, MPH
December 30, 2025
2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption
In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …
Marc Samuels, JD, MPH
December 16, 2025
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
Why is Medicare Data Central to IRA Negotiations?
The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …
The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development
Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …
ADVI Analysis: HRSA 340B Covered Entity Audits
Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …
Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions
In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.